Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Seres Therapeutics (NASDAQ:MCRB) with a $1.25 price target.
August 14, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Seres Therapeutics with a $1.25 price target.
The reaffirmation of a Buy rating and a specific price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100